NeurAxis, Inc. NRXS
6.86 USD +0.28 (+4.26%)
At closeNov 4, 2026, 7:43 PM EST
6.76 -0.10 -1.46%
After hours · Nov 4, 7:43 PM ET
6.51 Day range 6.87
2.31 52-week range 8.81
- YTD
- +51.10%
- 1 year
- +170.08%
News
globenewswire.com NeurAxis to Host Third Quarter 2026 Results and Business Update Call on Monday, November 9, 2026 CARMEL, Ind., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing…
benzinga.com NeurAxis Announces Its Medical Policy Coverage Now Serves Over 26M Medical Plan Members NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today
globenewswire.com NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives Total national coverage footprint for PENFS increases to over 147 million covered lives Total national coverage footprint for PENFS increases to over 147 million covered lives
defenseworld.net Reviewing NeurAxis (NASDAQ:NRXS) and NovoCure (NASDAQ:NVCR) NeurAxis (NASDAQ: NRXS - Get Free Report) and NovoCure (NASDAQ: NVCR - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies…
defenseworld.net Financial Review: Solventum (NYSE:SOLV) vs. NeurAxis (NASDAQ:NRXS) NeurAxis (NASDAQ: NRXS - Get Free Report) and Solventum (NYSE: SOLV - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based…
globenewswire.com NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic…
defenseworld.net Financial Review: NeurAxis (NASDAQ:NRXS) & MariMed (OTCMKTS:MRMD) MariMed (OTCMKTS:MRMD - Get Free Report) and NeurAxis (NASDAQ: NRXS - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 354.9% to $7.37 during Wednesday's regular session. The company's market cap stands at $4.9 million. Q/C Technologies (NASDAQ:QCLS) shares…
globenewswire.com NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic…
globenewswire.com NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for…
zacks.com Neuraxis Gains Nearly 137% in a Year: What's Driving the Stock? NRXS is benefiting from stronger IB-Stim volumes, broader reimbursement and VA access, but incomplete payer coverage and cash needs remain challenges.
seekingalpha.com NeurAxis, Inc. (NRXS) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript NeurAxis, Inc. (NRXS) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript
zacks.com Is Kodak having a "Kodak moment?" 2 watchlist stocks. KODK and NRXS are worth watching for their growth.
zacks.com NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up NeurAxis delivers record second-quarter 2026 revenues as stronger IB-Stim demand, higher pricing and an improved reimbursement mix lift gross margin.
seekingalpha.com NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript
benzinga.com Neuraxis Q2 EPS $(0.19) Beats $(0.32) Estimate, Sales $1.929M Miss $2.000M Estimate Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.32) by 40.63 percent. This is a 13.64 percent increase over losses of $(0.22) per…
globenewswire.com NeurAxis Expands Payer Coverage with New Policies CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 121.2% to $6.99 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 million. Supernus…
globenewswire.com NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026 CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing…
seekingalpha.com NeurAxis, Inc. (NRXS) Q1 2026 Earnings Call Transcript NeurAxis, Inc. (NRXS) Q1 2026 Earnings Call Transcript
benzinga.com Neuraxis Reports Q1 2026 Results: Full Earnings Call Transcript 
benzinga.com Earnings Scheduled For May 12, 2026 
globenewswire.com NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth CARMEL, Ind., May 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic…
benzinga.com Neuraxis Q1 EPS $(0.18) Beats $(0.19) Estimate, Sales $1.607M Beat $1.450M Estimate Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 45.45 percent increase over losses of $(0.33) per…
globenewswire.com NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026 CARMEL, Ind., May 05, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing…
globenewswire.com NeurAxis Expands Payer Coverage with Four New Medical Policies CARMEL, Ind., April 22, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic…
globenewswire.com NeurAxis, Inc. Announces Preferred Stock Dividend CARMEL, Ind., April 10, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for…
benzinga.com Craig-Hallum Maintains Buy on Neuraxis, Raises Price Target to $13 Craig-Hallum analyst Chase Knickerbocker maintains Neuraxis (AMEX:NRXS) with a Buy and raises the price target from $8 to $13.- benzinga.com Earnings Scheduled For March 19, 2026
- benzinga.com Neuraxis Q4 EPS $(0.17) Beats $(0.21) Estimate, Sales $968.127K Beat $850.000K Estimate Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.21) by 20.93 percent. This is a 26.09 percent increase over losses of $(0.23) per…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com NeurAxis Announces Category I CPT Code For Percutaneous Electrical Nerve Field Stimulation Is In Effect The new CPT code reflects the latest efficacious medical care available to patients, facilitating adoption and utilization.The assignment of a Category I CPT® code demonstrates a strong message to…
- benzinga.com Craig-Hallum Maintains Buy on Neuraxis, Raises Price Target to $8 Craig-Hallum analyst Chase Knickerbocker maintains Neuraxis (AMEX:NRXS) with a Buy and raises the price target from $7 to $8.
benzinga.com NeurAxis Rolls Out New Medical Policy Coverage For Percutaneous Electrical Nerve Field Stimulation NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and…- benzinga.com Neuraxis Q3 EPS $(0.24) Misses $(0.17) Estimate, Sales $811.414K Miss $1.000M Estimate Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.17) by 41.18 percent. This is a 4 percent increase over losses of $(0.25) per…
benzinga.com Neuraxis Earnings Preview - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Earnings Scheduled For August 12, 2025
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings 
benzinga.com Nasdaq Falls 100 Points; Home Depot Sales Top Views 
benzinga.com Earnings Scheduled For May 12, 2025 
benzinga.com Earnings Scheduled For March 20, 2025 - benzinga.com Earnings Scheduled For November 12, 2024